The pharmaceutical community is excited with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 agonist that’s showing significant efficacy in clinical trials for addressing obesity. Unlike some existing weight loss treatments, retatrutide appears to provide a significant substantial decrease in body size and benefit metabolic heal… Read More